论文部分内容阅读
目的探讨生存素(survivin)在乳腺癌表达及其与Caspase-3和临床相关因素的关系。方法采用免疫组化SP法检测生存素在正常乳腺组织(14例)、乳腺增生性病变(14例)、乳腺非浸润性癌(20例)和乳腺浸润性癌组织(52例)中的表达以及Caspase-3/CerbB-2/Ki67/p53/ER/PR在乳腺癌组织中的表达。结果生存素在这四组中阳性率分别为21.4%、35.7%、60.6%、71.2%(P<0.05)。淋巴结转移者生存素表达率高于无淋巴结转移者(P<0.05),生存素与Caspase-3在乳腺癌表达呈负相关(P<0.05);生存素表达阳性的乳腺癌Ki67/p53的标记指数(48.57±23.07)/(32.76±33.37)明显高于表达阴性的乳腺癌细胞Ki67的标记指数(21.30±20.50)/(15.43±24.44)(P<0.05)。结论生存素在乳腺癌进展中表达上调,提示可能通过与执行型Caspase-3结合,抑制其活性,从而阻止细胞凋亡,促进了细胞增殖与乳腺癌发生、发展;生存素有望成为乳腺癌诱导凋亡治疗的新靶点。
Objective To investigate the expression of survivin in breast cancer and its relationship with Caspase-3 and clinically relevant factors. Methods Immunohistochemical SP method was used to detect the expression of survivin in normal breast tissue (14 cases), benign breast lesions (14 cases), non-invasive breast cancer (20 cases) and invasive breast cancer (52 cases) And the expression of Caspase-3 / CerbB-2 / Ki67 / p53 / ER / PR in breast cancer tissues. Results The positive rates of survivin in these four groups were 21.4%, 35.7%, 60.6% and 71.2%, respectively (P <0.05). The positive rate of survivin expression in lymph node metastasis was significantly higher than that in no lymph node metastasis (P <0.05). The expression of survivin and Caspase-3 in breast cancer was negatively correlated (P <0.05). The positive rate of survivin expression in breast cancer Ki67 / p53 The index (48.57 ± 23.07) / (32.76 ± 33.37) was significantly higher than that of negative Ki67 breast cancer cells (21.30 ± 20.50) / (15.43 ± 24.44) (P <0.05). Conclusions Survivin is up-regulated in the progression of breast cancer, suggesting that it may inhibit its activity by binding to executive Caspase-3, thus preventing cell apoptosis and promoting cell proliferation and breast cancer development. Survivin is expected to be an inducer of breast cancer A new target of apoptosis treatment.